Shimadzu Europe
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

VITTA GROUP logo

Inivos Scientific rebrands to VITTA Group

, 25 January 2023/in E-News /by panglobal

Inivos Scientific, the parent company behind Edulab and Science & Chemical Supplies (SciChem), has rebranded and restructured the business to reflect its evolution and strategic growth plans.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/VITTA-GROUP_logo.jpg 464 572 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:23:482023-01-25 10:25:35Inivos Scientific rebrands to VITTA Group
shutterstock 2029745360

EpiEndo commences Phase 2a Trial for EP395 in COPD patients

, 25 January 2023/in E-News /by panglobal

EpiEndo Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. EP395 is an orally available macrolide or ‘Barriolide’, with reduced antimicrobial resistance potential, which aims to address the unmet medical need […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/shutterstock_2029745360-scaled-e1680865992221.jpg 600 900 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:21:142023-01-25 10:21:14EpiEndo commences Phase 2a Trial for EP395 in COPD patients
Coriolis Bruce Kerwin

Coriolis Pharma appoints formulation and drug development expert Bruce Kerwin to Scientific Advisory Board

, 25 January 2023/in E-News /by panglobal

Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of pharmaceutical drugs, including cell and gene therapy products and vaccines, is strengthening its scientific advisory board with the appointment of Bruce Kerwin.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/Coriolis_-Bruce_Kerwin.png 675 1200 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:19:262023-01-25 10:35:24Coriolis Pharma appoints formulation and drug development expert Bruce Kerwin to Scientific Advisory Board
shutterstock 1110645284

Bioventure, Minapharm Pharmaceuticals and MiGenTra sign exclusive agreement for commercialization of multiple biosimilar candidates of Alvotech in the MENA

, 25 January 2023/in E-News /by panglobal

Bioventure, a Dubai-based pharmaceutical company, Minapharm Pharmaceuticals, a Cairo-based pharmaceutical company, and MiGenTra, a Berlin-based pharmaceutical company, have signed an exclusive license agreement for the commercialization of multiple biosimilar candidates developed and manufactured by Alvotech, in Egypt and eighteen additional countries in Africa and the Middle East.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/shutterstock_1110645284-scaled-e1680866022267.jpg 600 1187 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:17:182023-01-25 10:17:31Bioventure, Minapharm Pharmaceuticals and MiGenTra sign exclusive agreement for commercialization of multiple biosimilar candidates of Alvotech in the MENA
CardiNor Produkt Web 02 1

CardiNor enter into a distribution agreement with Demeditec Diagnostics GmbH for the CE marked CardiNor Secretoneurin ELISA test

, 25 January 2023/in E-News /by panglobal

Cardiovascular DX company CardiNor AS today announces that it has signed an exclusive agreement with Demeditec for sales of the CE marked CardiNor Secretoneurin ELISA test in Germany. In addition, the agreement gives Demeditec the right to sell the test, on non-exclusive basis, in 15 countries outside Europe which includes India, South Korea, Mexico and […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/CardiNor-Produkt_Web_02-1-scaled-e1680865951256.jpg 600 899 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:07:572023-01-25 10:14:25CardiNor enter into a distribution agreement with Demeditec Diagnostics GmbH for the CE marked CardiNor Secretoneurin ELISA test
agilent new centre

Agilent opens Customer Experience Center highlighting genomics and diagnostics solutions

, 25 January 2023/in E-News /by panglobal

Agilent Technologies has opened a new Customer Experience Center (CEC) in Lexington, Massachusetts, U.S., focused on solutions from Agilent genomics and diagnostics product portfolios. The facility will serve as a regional hub for Agilent representatives to showcase and demonstrate both product capabilities and complete workflow solutions to customers.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/agilent-new-centre-scaled-e1680866078114.jpg 600 800 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:02:492023-01-25 10:02:49Agilent opens Customer Experience Center highlighting genomics and diagnostics solutions
image005

Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field

, 23 January 2023/in E-News /by panglobal

Supporting Master’s student in Prof Helen Walden’s laboratory Project aims to determine USP30 structure to inform the design and discovery of novel inhibitors

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/image005.png 75 342 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-23 12:28:472023-01-23 12:30:46Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field
image001

Beckman Coulter Life Sciences Completes First Phase of Colorado Research and Development Hub with Grand Opening of $10 Million Loveland Offices

, 23 January 2023/in E-News /by panglobal

Company Announces Initiation of Second Phase of Expansion Project

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/image001.jpg 1005 1460 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-23 11:42:142023-01-23 11:42:14Beckman Coulter Life Sciences Completes First Phase of Colorado Research and Development Hub with Grand Opening of $10 Million Loveland Offices
CardiNor Produkt Web 02

CardiNor enter into a distribution agreement with Demeditec Diagnostics GmbH for the CE marked CardiNor Secretoneurin ELISA test

, 19 January 2023/in E-News /by panglobal

Cardiovascular DX company CardiNor AS today announces that it has signed an exclusive agreement with Demeditec for sales of the CE marked CardiNor Secretoneurin ELISA test in Germany. In addition, the agreement gives Demeditec the right to sell the test, on non-exclusive basis, in 15 countries outside Europe which includes India, South Korea, Mexico and […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/CardiNor-Produkt_Web_02-scaled.jpg 1708 2560 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-19 09:17:082023-01-19 09:22:11CardiNor enter into a distribution agreement with Demeditec Diagnostics GmbH for the CE marked CardiNor Secretoneurin ELISA test
HEK293ViralFeed

FUJIFILM Irvine Scientific Launches HEK293 Feed, Specifically Designed for Viral Vector Production

, 13 January 2023/in E-News /by panglobal

Chemically defined, BalanCD HEK293 Viral Feed enhances viral vector production for gene therapy applications and viral vector-based vaccines

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/HEK293ViralFeed-scaled.jpg 1795 2560 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-13 09:25:022023-01-13 10:15:38FUJIFILM Irvine Scientific Launches HEK293 Feed, Specifically Designed for Viral Vector Production
Page 45 of 227«‹4344454647›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

November 2025

CLi Cover nov 2025
13 November 2025

New Chromsystems Product for Antiepileptic Drugs Testing

11 November 2025

Trusted analytical solutions for reliable results

10 November 2025

Chromsystems | Therapeutic Drug Monitoring by LC-MS/MS

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription